News | July 28, 2021
Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The US business faced price erosion due to increased competition.
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Subscribe To Our Newsletter & Stay Updated
